They randomly assigned 702 patients with high-risk, muscle-invasive bladder cancer who had undergone bladder-removal surgery to receive adjuvant therapy with pembrolizumab every three weeks for a ...

Discover a study exploring novel drug combinations and genetic insights transforming advanced bladder cancer treatment.

They randomly assigned 702 patients with high-risk, muscle-invasive bladder cancer who had undergone bladder-removal surgery to receive adjuvant therapy with pembrolizumab every three weeks for a ...

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free ...

Enfortumab vedotin and pembrolizumab combination shows a 49% reduction in mortality risk for advanced bladder cancer compared to chemotherapy. ASCO GU symposium focuses on antibody-drug conjugates ...

If you or a loved one is navigating an advanced bladder cancer diagnosis, visit PADCEV.com† to learn more about Armando and Laura's story and discover more about PADCEV with pembrolizumab as a ...

New treatments reshape metastatic and muscle-invasive bladder cancer therapy. ... So now most patients in the frontline metastatic setting will get [the] EV and pembrolizumab combination, ...

Addition of neoadjuvant and adjuvant pembrolizumab to standard care significantly improves event-free survival.

Phase 3 data support “changing the current standard of care to now include neoadjuvant and adjuvant pembrolizumab,” according to Ravindra Uppaluri, MD, PhD.

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free ...